Zyprexa Adhera Gets Advisory Committee Review Feb. 6
This article was originally published in The Pink Sheet Daily
Executive Summary
Incidence of somnolence seen with the long-acting version of Lilly’s atypical antipsychotic will be among the topics discussed.
You may also be interested in...
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.
Lilly Zyprexa, Symbyax Labeling Strengthened
Update elevates information on weight gain and hyperlipidemia from adverse event precaution to “Warning” status and adds to elevated blood sugar warning.